
Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more
- Year: 2022
- Scope: 10 Years
- Region: Europe
- Pages: 421
- Published Date: 05/20/2022
- Type: MedSuite
The total European orthopedic biomaterials market is growing at a rate of 2%, which will take the 2021 market value of €550 million up to €632 million by 2028.
The full report suite on the European market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) and synthetic bone grafts. The report also includes orthopedic growth factors, cell therapies, hyaluronic acid (HA) viscosupplementation and cartilage repair.
MARKET REPORT DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2028, and Historical Data to 2018
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Procedure Volumes
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- COVID-19 Impact Analysis
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET TRENDS
Demographic factors continue to be the largest driver within the orthopedic biomaterials market in Europe. This is primarily due to the growing elderly population, which is correlated to the incidence of osteoarthritis, osteoporosis, osteomalacia, rheumatoid arthritis and other bone diseases. As the aging population in Europe is growing alongside the majority of baby boomers reaching retirement age, the demand for bone graft substitutes will also increase. A lower level of physical activity is more common among older adults.
EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET SHARE INSIGHTS
Overall, within the European orthopedic biomaterials market there are two dominant competitors: Fidia and Medtronic.In 2021, Fidia retained its spot as the leader within the European orthopedic biomaterials market. This is due to its orthopedic HA viscosupplementation products, Hyalubrix® and Hyalgan®, which maintained a strong presence in the market.
MARKET SEGMENTATION SUMMARY
You can view all these included reports and segmentation here:
- Bone Graft Substitutes Market – MedCore – Includes:
- Allografts, demineralized bone matrices (DBM) and synthetic bone grafts substitutes
- Orthopedic Growth Factor Market – MedCore – Includes:
- Segments for spine and tibial fracture
- Orthopedic Cell Therapy Market – MedCore – Includes:
- Platelet-rich plasma and bone marrow concentration segments
- Hyaluronic Acid Viscosupplementation Market – MedCore – Includes:
- Single-injection, Two-injection, Three-Injection, and Five-Injection products
- Orthopedic Cartilage Repair Market – MedCore — Includes:
- Osteochondral allografts, meniscal allografts, ACI products and osteochondral autografts
Global Research Scope Summary
Report Attribute | Details |
---|---|
Regions | Europe |
Base Year | 2021 |
Forecast | 2022-2028 |
Historical Data | 2018-2021 |
Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
Qualitative Coverage | COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
Table of Contents
TABLE of CONTENTS |
List of Figures |
List of Charts |
executive summary |
European Orthopedic Biomaterials Market Overview |
Competitive Analysis |
Market Trends |
Market Developments |
Procedure Numbers |
Markets Included |
Key Report Updates |
Version History |
research methodology |
Step 1: Project Initiation & Team Selection |
Step 2: Prepare Data Systems and Perform Secondary Research |
Step 3: Preparation for Interviews & Questionnaire Design |
Step 4: Performing Primary Research |
Step 5: Research Analysis: Establishing Baseline Estimates |
Step 6: Market Forecast and Analysis |
Step 7: Identify Strategic Opportunities |
Step 8: Final Review and Market Release |
Step 9: Customer Feedback and Market Monitoring |
impact of covid-19 on THE European Orthopedic Biomaterials Market |
2.1 Introduction |
2.1.1 Treatable Population |
2.2 Country Profiles |
2.3 Analysis By Market Segment |
2.3.1 Worst Case Scenario |
2.3.2 Base Case Scenario |
2.3.3 Best Case Scenario |
Product Assessment |
3.1 Introduction |
3.2 Product Portfolios |
3.2.1 Bone Graft Substitutes |
3.2.2 Growth Factors |
3.2.2.1.1 NELL-1 Bone Biologics |
3.2.2.1.2 INFUSE® by Medtronic |
3.2.2.1.3 OsteoAMP® by Bioventus Surgical |
3.2.2.1.4 OP-1™ by Stryker / Olympus Biotech (delisted) |
3.2.2.1.5 The Osteogrow Study |
3.2.2.2 Other Products |
3.2.2.2.1 AUGMENT® Bone Graft |
3.2.2.2.2 Amplex® Osteobiologic Bone Graft Substitute |
3.2.2.2.3 i-Factor™ Peptide Bone Matrix |
3.2.3 Cellular Allografts (Stem Cell) |
3.2.4 Cell Therapy |
3.2.4.1 Platelet-Rich Plasma |
3.2.4.2 Bone Marrow Aspirate Concentrate |
3.2.5 Hyaluronic Acid Viscosupplementation (HAV) |
3.2.6 Cartilage Repair |
3.3 Regulatory Issues and Recalls |
3.3.1 Bioventus |
3.3.1.1 Bone Graft Substitute |
3.3.2 Exactech |
3.3.2.1 Bone Graft Substitute |
3.3.3 Medtronic |
3.3.3.1 Bone Graft Substitute |
3.3.4 Sanofi |
3.3.4.1 Hyaluronic Acid Viscosupplementation |
3.3.5 Wright Medical (Stryker) |
3.3.5.1 Bone Graft Substitute |
3.3.6 Xtant |
3.3.6.1 Bone Graft Substitute |
3.3.7 Zimmer Biomet |
3.3.7.1 Growth Factor |
3.4 Clinical Trials |
3.4.1 Arthrex |
3.4.1.1 Bone Graft Substitute |
3.4.2 DePuy Synthes |
3.4.2.1 Cellular Allograft |
3.4.3 RTI Surgical |
3.4.3.1 Bone Graft Substitute |
3.4.4 Stryker |
3.4.4.1 Bone Graft Substitute |
3.4.5 Others |
3.4.5.1 Bone Graft Substitute |
3.4.5.2 Growth Factor |
3.4.5.3 Cellular Allograft |
3.4.5.4 Cell Therapy |
3.4.5.5 Hyaluronic Acid Viscosupplementation |
3.4.5.6 Cartilage Repair |
European Orthopedic Biomaterials Market Overview |
4.1 Introduction |
4.2 Currency Exchange Rate |
4.3 Market Overview & Trend Analysis |
4.4 Drivers and Limiters |
4.4.1 Market Drivers |
4.4.2 Market Limiters |
4.5 Competitive Market Share Analysis |
4.6 Mergers and Acquisitions |
4.7 Company Profiles |
4.7.1 Arthrex |
4.7.2 Bioventus |
4.7.3 DePuy Synthes |
4.7.4 Ferring Pharmaceuticals |
4.7.5 Fidia Farmaceutici |
4.7.6 Harvest Technologies (Terumo BCT) |
4.7.7 Medtronic |
4.7.8 Musculoskeletal Transplant Foundation (MTF) |
4.7.9 NuVasive |
4.7.10 Orthofix |
4.7.11 RTI Surgical |
4.7.12 Sanofi |
4.7.13 Stryker |
4.7.14 Vericel Corporation |
4.7.15 Zimmer Biomet |
4.8 SWOT Analysis |
4.8.1 Arthrex |
4.8.2 Bioventus |
4.8.3 DePuy Synthes |
4.8.4 Ferring Pharmaceuticals |
4.8.5 Fidia Farmaceutici |
4.8.6 Harvest Technologies (Terumo BCT) |
4.8.7 Medtronic |
4.8.8 Musculoskeletal Transplant Foundation (MTF) |
4.8.9 NuVasive |
4.8.10 Orthofix |
4.8.11 RTI Surgical |
4.8.12 Sanofi |
4.8.13 Stryker |
4.8.14 Vericel |
4.8.15 Zimmer Biomet |
Country Profiles |
5.1 Introduction |
5.1.1 GDP Per Capita |
5.1.2 Price Index |
5.2 Germany |
5.3 France |
5.4 United Kingdom |
5.5 Italy |
5.6 Spain |
5.7 Benelux |
5.8 Scandinavia |
5.9 Austria |
5.10 Switzerland |
5.11 Portugal |
Procedure Numbers |
6.1 Introduction |
6.2 Procedures |
6.2.1 Orthopedic Bone Grafting Procedures |
6.2.1.1 Orthopedic Bone Grafting Procedures by Material |
6.2.1.2 Orthopedic Bone Grafting Procedures by Indication |
6.2.1.2.1 Average Units Used per Procedure by Indication |
6.2.1.3 Allograft Procedures by Indication |
6.2.1.4 DBM Procedures by Indication |
6.2.1.5 Synthetic Procedures by Indication |
6.2.1.6 Orthopedic Bone Grafting Procedures by Care Setting |
6.2.2 Orthopedic Growth Factor Procedures |
6.2.2.1 Orthopedic Growth Factor Procedures by Indication |
6.2.2.2 Orthopedic Growth Factor Procedures by Care Setting |
6.2.3 Orthopedic Cell Therapy Procedures |
6.2.3.1 Orthopedic Cell Therapy Procedures by Material Type |
6.2.3.2 Platelet-Rich Plasma Procedures |
6.2.3.3 Bone Marrow Aspirate Concentrate Procedures |
6.2.3.1 Orthopedic Cell Therapy Procedures by Care Setting |
6.2.4 Hyaluronic Acid Viscosupplementation Procedures |
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle |
6.2.4.1 Hyaluronic Acid Viscosupplementation Procedures by Care Setting |
6.2.5 Orthopedic Cartilage Repair Procedures |
6.2.5.1 Orthopedic Cartilage Repair Procedures by Type |
6.2.5.2 Orthopedic Cartilage Repair Procedures by Care Setting |
orthopedic Bone Graft Substitute Market |
7.1 Introduction |
7.2 Market Overview |
7.3 Market Analysis and Forecast |
7.3.1 Total Bone Graft Substitute Market |
7.3.2 Allograft Bone Graft Substitute Market |
7.3.3 Demineralized Bone Matrix Bone Graft Substitute Market |
7.3.4 Synthetic Bone Graft Substitute Market |
7.4 Unit Analysis |
7.4.1 Total Bone Graft Substitute Unit Analysis |
7.4.2 Allograft Bone Graft Substitute Unit Analysis |
7.4.2.1 Allograft Bone Graft Substitute Units Sold by Indication |
7.4.2.1.1 Spine Allograft Bone Graft Substitute Units Sold by Anatomy |
7.4.2.1.2 Trauma Allograft Bone Graft Substitute Units Sold by Anatomy |
7.4.2.1.3 Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy |
7.4.2.1.4 Foot Reconstruction Allograft Bone Graft Substitute Units Sold |
7.4.2.1.5 Craniomaxillofacial Allograft Bone Graft Substitute Units Sold |
7.4.2.1.6 Oncology Allograft Bone Graft Substitute Units Sold |
7.4.3 Demineralized Bone Matrix Allograft Unit Analysis |
7.4.3.1 Demineralized Bone Matrix Allograft Units Sold by Indication |
7.4.3.1.1 Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy |
7.4.3.1.2 Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy |
7.4.3.1.3 Craniomaxillofacial Demineralized Bone Matrix Allograft Units Sold |
7.4.4 Synthetic Bone Graft Substitute Unit Analysis |
7.4.4.1 Synthetic Bone Graft Substitute Units Sold by Indication |
7.4.4.1.1 Spine Synthetic Bone Graft Substitute Units Sold by Anatomy |
7.4.4.1.2 Trauma Synthetic Bone Graft Substitute Units Sold by Anatomy |
7.4.4.1.3 Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy |
7.4.4.1.4 Foot Reconstruction Synthetic Bone Graft Substitute Units Sold |
7.4.4.1.5 Craniomaxillofacial Synthetic Bone Graft Substitute Units Sold |
7.4.4.1.6 Oncology Synthetic Bone Graft Substitute Units Sold |
7.5 Drivers and Limiters |
7.5.1 Market Drivers |
7.5.2 Market Limiters |
7.6 Competitive Market Share Analysis |
ORthopedic Growth Factor Market |
8.1 Introduction |
8.1.1 BMP-2 (Medtronic) |
8.2 Market Overview |
8.3 Market Analysis and Forecast |
8.3.1 Orthopedic Growth Factor Market |
8.4 Unit Analysis |
8.4.1 Spine Orthopedic Growth Factor Unit Analysis |
8.4.2 Tibial Fracture Orthopedic Growth Factor Unit Analysis |
8.5 Drivers and Limiters |
8.5.1 Market Drivers |
8.5.2 Market Limiters |
8.6 Competitive Market Share Analysis |
Orthopedic Cell Therapy Market |
9.1 Introduction |
9.2 Market Overview |
9.3 Market Analysis and Forecast |
9.3.1 Platelet-Rich Plasma Market |
9.3.2 Bone Marrow Aspirate Concentrate Market |
9.4 Unit Analysis |
9.4.1 Platelet-Rich Plasma Units Sold by Indication |
9.4.1.1 Soft Tissue Platelet-Rich Plasma Units Sold |
9.4.1.2 Spine Platelet-Rich Plasma Units Sold |
9.4.1.3 Cardiac Platelet-Rich Plasma Units Sold |
9.4.1.4 Orthopedic Platelet-Rich Plasma Units Sold |
9.4.1.5 Plastics Platelet-Rich Plasma Units Sold |
9.4.2 Bone Marrow Aspirate Concentrate Units Sold by Indication |
9.4.2.1 Spine Bone Marrow Aspirate Concentrate Units Sold |
9.4.2.2 Soft Tissue Bone Marrow Aspirate Concentrate Units Sold |
9.4.2.3 Trauma Bone Marrow Aspirate Concentrate Units Sold |
9.4.2.4 Joint Reconstruction Bone Marrow Aspirate Concentrate Units Sold |
9.5 Drivers and Limiters |
9.5.1 Market Drivers |
9.5.2 Market Limiters |
9.6 Competitive Market Share Analysis |
Hyaluronic Acid Viscosupplementation Market |
10.1 Introduction |
10.1.1 Benefits of Viscosupplementation |
10.1.2 Synovial Fluid |
10.1.3 Product Types |
10.2 Market Overview |
10.3 Market Analysis and Forecast |
10.3.1 Total Hyaluronic Acid Viscosupplementation Market |
10.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market |
10.3.3 Two-Injection Hyaluronic Acid Viscosupplementation Market |
10.3.4 Three-Injection Hyaluronic Acid Viscosupplementation Market |
10.3.5 Five-Injection Hyaluronic Acid Viscosupplementation Market |
10.4 Drivers and Limiters |
10.4.1 Market Drivers |
10.4.2 Market Limiters |
10.5 Competitive Market Share Analysis |
Orthopedic Cartilage Repair Market |
11.1 Introduction |
11.1.1 Anatomy |
11.1.2 Methods for Cartilage Repair |
11.1.2.1 Osteochondral Allograft Transfer |
11.1.2.2 Autologous Chondrocyte Implantation (ACI) |
11.1.2.3 Meniscal Allograft Transplantation |
11.1.2.4 Osteochondral Autograft |
11.2 Market Overview |
11.3 Market Analysis and Forecast |
11.3.1 Osteochondral Allograft Market |
11.3.2 Meniscal Allograft Market |
11.3.3 Autologous Chondrocyte Implantation Market |
11.3.4 Osteochondral Autograft Market |
11.4 Drivers and Limiters |
11.4.1 Market Drivers |
11.4.2 Market Limiters |
11.5 Competitive Market Share Analysis |
Abbreviations |
Companies Included:
· Adistem | · DePuy Synthes |
· Alphatec | · Documedica |
· Anika Therapeutics | · Exactech |
· Arthrex | · Ferring |
· Baxter | · Fidia |
· BioCell | · Finceramica |
· Biocomposites | · Geistlich |
· Bioiberica | · Harvest (Terumo) |
· Biomatlante | · IBSA Pharma |
· Bioventus | · Integra LifeSciences |
· Bonalive | · Isto |
· Cerapedics | · Kuros |
· CO.DON | · LCA Pharmaceuticals |
· CONMED | · Medtronic |
· Croma-Pharma | · NovaBone |
· Curasan | · Nuo Therapeutics |
List of Charts
Chart 1‑1: Orthopedic Biomaterials Market by Segment, Europe, 2021 – 2028 |
Chart 1‑2: Orthopedic Biomaterials Market Overview, Europe, 2021 & 2028 |
Chart 2‑1: Multi-Scenario Orthopedic Biomaterials Market Forecast, Europe, 2018 – 2028 (€M) |
Chart 4‑1: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 |
Chart 4‑2: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 |
Chart 5‑1: Country Profile, Germany, 2021 |
Chart 5‑2: Country Profile, France, 2021 |
Chart 5‑3: Country Profile, United Kingdom, 2021 |
Chart 5‑4: Country Profile, Italy, 2021 |
Chart 5‑5: Country Profile, Spain, 2021 |
Chart 5‑6: Country Profile, Benelux, 2021 |
Chart 5‑7: Country Profile, Scandinavia, 2021 |
Chart 5‑8: Country Profile, Austria, 2021 |
Chart 5‑9: Country Profile, Switzerland, 2021 |
Chart 5‑10: Country Profile, Portugal, 2021 |
Chart 7‑1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 |
Chart 7‑2: Leading Competitors, Orthopedic Bone Graft Substitute Market, Europe, 2021 |
Chart 9‑1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 |
Chart 9‑2: Leading Competitors, Orthopedic Cell Therapy Market, Europe, 2021 |
Chart 10‑1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 |
Chart 10‑2: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 |
Chart 11‑1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 |
Chart 11‑2: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 |
List of Figures
Figure 1‑1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2021 |
Figure 1‑2: Companies Researched in this Report (1 of 2) |
Figure 1‑3: Companies Researched in this Report (2 of 2) |
Figure 1‑4: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (1 of 2) |
Figure 1‑5: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe (2 of 2) |
Figure 1‑6: Recent Events in the Orthopedic Biomaterials Market, Europe, 2018 – 2021 |
Figure 1‑7: Orthopedic Biomaterials Procedures Covered, Europe (1 of 2) |
Figure 1‑8: Orthopedic Biomaterials Procedures Covered, Europe (2 of 2) |
Figure 1‑9: Orthopedic Biomaterials Markets Covered, Europe (1 of 2) |
Figure 1‑10: Orthopedic Biomaterials Markets Covered, Europe (2 of 2) |
Figure 1‑11: Key Report Updates (1 of 2) |
Figure 1‑12: Key Report Updates (2 of 2) |
Figure 1‑13: Version History |
Figure 2‑1: Orthopedic Biomaterials Market by Segment, Worst Case Scenario, Europe, 2018 – 2028 (€M) |
Figure 2‑2: Orthopedic Biomaterials Market by Segment, Base Case Scenario, Europe, 2018 – 2028 (€M) |
Figure 2‑3: Orthopedic Biomaterials Market by Segment, Best Case Scenario, Europe, 2018 – 2028 (€M) |
Figure 3‑1: Bone Graft Substitutes Products by Company (1 of 4) |
Figure 3‑2: Bone Graft Substitutes Products by Company (2 of 4) |
Figure 3‑3: Bone Graft Substitutes Products by Company (3 of 4) |
Figure 3‑4: Bone Graft Substitutes Products by Company (4 of 4) |
Figure 3‑5: Growth Factor Products by Company |
Figure 3‑6: Estimates of Funding for Stem Cell Research |
Figure 3‑7: Cellular Allograft Products by Company |
Figure 3‑8: Cell Therapy Products by Company |
Figure 3‑9: Hyaluronic Acid Viscosupplementation by Products by Company |
Figure 3‑10: Cartilage Repair Products by Company |
Figure 3‑11: Class 2 Device Recall Bioactive Bone Graft Putty |
Figure 3‑12: Class 2 Device Recall Opteform Allograft Disc |
Figure 3‑13: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT |
Figure 3‑14: Class 2 Device Recall SynviscOne |
Figure 3‑15: Class 2 Device Recall PROSTIM 10cc INJECTABLE |
Figure 3‑16: Class 2 Device Recall OsteoSelect Demineralized Bone Matrix (DBM) Putty |
Figure 3‑17: Class 1 Device Recall EBI Osteogen Implantable Bone Growth Stimulator |
Figure 2-18: Demineralized Bone Matrix Rotator Cuff Study |
Figure 2-19: ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis (ViviGen) |
Figure 2-20: Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease (ViviGen) |
Figure 2-21: Prospective SPINE Registry (SPINE) |
Figure 2-22: ACDF Using Structural Allograft vs. Tritanium C |
Figure 2-23: Long-term Safety and Effectiveness of AUGMENT® Injectable Bone Graft Compared to Autologous Bone Graft |
Figure 2-24: Rate of Bony Fusion Using NanoBone® Synthetic Bone Graft Versus Local Autologous Bone Graft. (BONE) |
Figure 2-25: Novel Porous Bioceramic Material as a Bone Substitute |
Figure 2-26: Evaluation of the Effectiveness of AMPLEX® Compared to Autogenous Bone Grafts |
Figure 2-27: Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care |
Figure 2-28: Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis (BMAC) |
Figure 2-29: A Prospective Study of Clinical Outcomes Following a Single Intradiscal Injection of Bone Marrow Aspirate Concentrate (BMAC) for Single Level Discogenic Low Back Pain |
Figure 2-30: Platelet-Rich Plasma (PRP) for Treatment of Symptomatic Lumbar Facet Syndrome of the Spine |
Figure 2-31: Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis (BMAC) |
Figure 2-32: The Effectiveness of Different Doses of Hyaluronic Acid Injections in Knee Osteoarthritis. |
Figure 2-33: Osteochondral Allograft in the Surgical Treatment of Basal Joint Arthritis |
Figure 2-34: Prospective Evaluation of ProChondrix CR for Repair of Articular Cartilage Defects on Femoral Condyle and Patella |
Figure 2-35: Phase 2 Clinical Trial of CartiLife® in the United States |
Figure 4‑1: Currency Exchange Rate, 2021 |
Figure 4‑2: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 4‑3: Orthopedic Biomaterials Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 4‑4: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (1 of 2) |
Figure 4‑5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2021 (2 of 2) |
Figure 4‑6: SWOT Analysis, Arthrex |
Figure 4‑7: SWOT Analysis, Bioventus |
Figure 4‑8: SWOT Analysis, DePuy Synthes |
Figure 4‑9: SWOT Analysis, Ferring Pharmaceuticals |
Figure 4‑10: SWOT Analysis, Fidia Farmaceutici |
Figure 4‑11: SWOT Analysis, Harvest Technologies |
Figure 4‑12: SWOT Analysis, Medtronic |
Figure 4‑13: SWOT Analysis, MTF |
Figure 4‑14: SWOT Analysis, NuVasive |
Figure 4‑15: SWOT Analysis, Orthofix |
Figure 4‑16: SWOT Analysis, RTI Surgical |
Figure 4‑17: SWOT Analysis, Genzyme (Sanofi) |
Figure 4‑18: SWOT Analysis, Stryker |
Figure 4‑19: SWOT Analysis, Vericel Corporation |
Figure 4‑20: SWOT Analysis, Zimmer Biomet |
Figure 6‑1: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 |
Figure 6‑2: Orthopedic Biomaterials Procedures by Segment, Europe, 2018 – 2028 |
Figure 6‑3: Orthopedic Bone Grafting Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑4: Orthopedic Bone Grafting Procedures by Material, Europe, 2018 – 2028 |
Figure 6‑5: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (1 of 2) |
Figure 6‑6: Orthopedic Bone Grafting Procedures by Indication, Europe, 2018 – 2028 (2 of 2) |
Figure 6‑7: Cervical Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑8: Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑9: Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑10: Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑11: Hip Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑12: Knee Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑13: Foot Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑14: Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑15: Oncology Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑16: Average Units Used per Procedure by Indication, Europe, 2018 – 2028 |
Figure 6‑17: Allograft Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑18: Allograft Procedures by Indication, Europe, 2018 – 2028 (1 of 2) |
Figure 6‑19: Allograft Procedures by Indication, Europe, 2018 – 2028 (2 of 2) |
Figure 6‑20: Allograft Cervical Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑21: Allograft Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑22: Allograft Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑23: Allograft Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑24: Allograft Hip Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑25: Allograft Knee Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑26: Allograft Foot Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑27: Allograft Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑28: Allograft Oncology Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑29: DBM Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑30: DBM Procedures by Indication, Europe, 2018 – 2028 |
Figure 6‑31: DBM Cervical Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑32: DBM Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑33: DBM Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑34: DBM Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑35: DBM Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑36: Synthetic Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑37: Synthetic Procedures by Indication, Europe, 2018 – 2028 (1 of 2) |
Figure 6‑38: Synthetic Procedures by Indication, Europe, 2018 – 2028 (2 of 2) |
Figure 6‑39: Synthetic Cervical Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑40: Synthetic Thoracolumbar Spine Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑41: Synthetic Non-Union Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑42: Synthetic Fresh Fracture Trauma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑43: Synthetic Hip Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑44: Synthetic Knee Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑45: Synthetic Foot Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑46: Synthetic Craniomaxillofacial Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑47: Synthetic Oncology Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑48: Orthopedic Bone Grafting Procedures by Care Setting, Europe, 2018 – 2028 |
Figure 6‑49: Orthopedic Growth Factor Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑50: Orthopedic Growth Factor Procedures by Indication, Europe, 2018 – 2028 |
Figure 6‑51: Spine Growth Factor Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑52: Trauma Growth Factor Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑53: Orthopedic Growth Factor Procedures by Care Setting, Europe, 2018 – 2028 |
Figure 6‑54: Orthopedic Cell Therapy Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑55: Orthopedic Cell Therapy Procedures by Material Type, Europe, 2018 – 2028 |
Figure 6‑56: Platelet-Rich Plasma Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑57: Bone Marrow Aspirate Concentrate Procedures by Indication, Europe, 2018 – 2028 |
Figure 6‑58: Orthopedic Cell Therapy Procedures by Care Setting, Europe, 2018 – 2028 |
Figure 6‑59: Hyaluronic Acid Viscosupplementation Total Injections by Country, Europe, 2018 – 2028 |
Figure 6‑60: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (1 of 2) |
Figure 6‑61: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Europe, 2018 – 2028 (2 of 2) |
Figure 6‑62: Single-Injection Cycles by Country, Europe, 2018 – 2028 |
Figure 6‑63: Two-Injection Cycles by Country, Europe, 2018 – 2028 |
Figure 6‑64: Three-Injection Cycles by Country, Europe, 2018 – 2028 |
Figure 6‑65: Five-Injection Cycles by Country, Europe, 2018 – 2028 |
Figure 6‑66: Hyaluronic Acid Viscosupplementation Procedures by Care Setting, Europe, 2018 – 2028 |
Figure 6‑67: Orthopedic Cartilage Repair Procedures by Type, Europe, 2018 – 2028 (1 of 2) |
Figure 6‑68: Autologous Chondrocyte Implantation Procedures by Country, Europe, 2018 – 2028 |
Figure 6‑69: Orthopedic Cartilage Repair Procedures by Care Setting, Europe, 2018 – 2028 |
Figure 7‑1: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 7‑2: Bone Graft Substitute Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 7‑3: Total Bone Graft Substitute Market, Europe, 2018 – 2028 |
Figure 7‑4: Units Sold by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 |
Figure 7‑5: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€) |
Figure 7‑6: Average Selling Price by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$) |
Figure 7‑7: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (€M) |
Figure 7‑8: Market Value by Country, Total Bone Graft Substitute Market, Europe, 2018 – 2028 (US$M) |
Figure 7‑9: Allograft Market, Europe, 2018 – 2028 |
Figure 7‑10: Units Sold by Country, Allograft Market, Europe, 2018 – 2028 |
Figure 7‑11: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (€) |
Figure 7‑12: Average Selling Price by Country, Allograft Market, Europe, 2018 – 2028 (US$) |
Figure 7‑13: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (€M) |
Figure 7‑14: Market Value by Country, Allograft Market, Europe, 2018 – 2028 (US$M) |
Figure 7‑15: Demineralized Bone Matrix Market, Europe, 2018 – 2028 |
Figure 7‑16: Units Sold by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 |
Figure 7‑17: Average Selling Price by Country, Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€) |
Figure 7‑18: Average Selling Price by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$) |
Figure 7‑19: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (€M) |
Figure 7‑20: Market Value by Country, Total Demineralized Bone Matrix Market, Europe, 2018 – 2028 (US$M) |
Figure 7‑21: Synthetic Market, Europe, 2018 – 2028 |
Figure 7‑22: Units Sold by Country, Synthetic Market, Europe, 2018 – 2028 |
Figure 7‑23: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (€) |
Figure 7‑24: Average Selling Price by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$) |
Figure 7‑25: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (€M) |
Figure 7‑26: Market Value by Country, Total Synthetic Market, Europe, 2018 – 2028 (US$M) |
Figure 7‑27: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (1 of 2) |
Figure 7‑28: Total Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 (2 of 2) |
Figure 7‑29: Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑30: Spine Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑31: Units Sold by Country, Cervical Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑32: Units Sold by Country, Thoracolumbar Spine Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑33: Trauma Allograft Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑34: Units Sold by Country, Non-Union Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑35: Units Sold by Country, Fresh Fracture Trauma Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑36: Large Joint Reconstruction Allograft Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 |
Figure 7‑37: Units Sold by Country, Hip Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑38: Units Sold by Country, Knee Large Joint Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑39: Units Sold by Country, Foot Reconstruction Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑40: Units Sold by Country, Craniomaxillofacial Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑41: Units Sold by Country, Oncology Allograft Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑42: Demineralized Bone Matrix Allograft Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑43: Spine Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 |
Figure 7‑44: Units Sold by Country, Cervical Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 |
Figure 7‑45: Units Sold by Country, Thoracolumbar Spine Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 |
Figure 7‑46: Trauma Demineralized Bone Matrix Allograft Units Sold by Anatomy, Europe, 2018 – 2028 |
Figure 7‑47: Units Sold by Country, Non-Union Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 |
Figure 7‑48: Units Sold by Country, Fresh Fracture Trauma Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 |
Figure 7‑49: Units Sold by Country, Craniomaxillofacial Demineralized Bone Matrix Allograft, Europe, 2018 – 2028 |
Figure 7‑50: Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑51: Spine Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 |
Figure 7‑52: Units Sold by Country, Cervical Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑53: Units Sold by Country, Thoracolumbar Spine Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑54: Trauma Synthetic Bone Graft Substitute Units Sold by Indication, Europe, 2018 – 2028 |
Figure 7‑55: Units Sold by Country, Non-Union Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑56: Units Sold by Country, Fresh Fracture Trauma Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑57: Large Joint Reconstruction Synthetic Bone Graft Substitute Units Sold by Anatomy, Europe, 2018 – 2028 |
Figure 7‑58: Units Sold by Country, Hip Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑59: Units Sold by Country, Knee Large Joint Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑60: Units Sold by Country, Foot Reconstruction Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑61: Units Sold by Country, Craniomaxillofacial Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑62: Units Sold by Country, Oncology Synthetic Bone Graft Substitute, Europe, 2018 – 2028 |
Figure 7‑63: Leading Competitors by Country, Orthopedic Bone Graft Substitute Market, Europe, 2021 |
Figure 8‑1: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 8‑2: Orthopedic Growth Factor Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 8‑3: Orthopedic Growth Factor Market, Europe, 2018 – 2028 |
Figure 8‑4: Units Sold (5 cc) by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 |
Figure 8‑5: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€) |
Figure 8‑6: Average Selling Price by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$) |
Figure 8‑7: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (€M) |
Figure 8‑8: Market Value by Country, Orthopedic Growth Factor Market, Europe, 2018 – 2028 (US$M) |
Figure 8‑9: Units Sold (5 cc) by Country, Spine Orthopedic Growth Factor Market, Europe, 2018 – 2028 |
Figure 8‑10: Units Sold (5 cc) by Country, Tibial Fracture Orthopedic Growth Factor Market, Europe, 2018 – 2028 |
Figure 8‑11: Leading Competitors by Country, Orthopedic Growth Factor Market, Europe, 2021 |
Figure 9‑1: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 9‑2: Orthopedic Cell Therapy Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 9‑3: Platelet-Rich Plasma Market, Europe, 2018 – 2028 |
Figure 9‑4: Units Sold (10cc) by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 |
Figure 9‑5: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€) |
Figure 9‑6: Average Selling Price by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$) |
Figure 9‑7: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (€M) |
Figure 9‑8: Market Value by Country, Platelet-Rich Plasma Market, Europe, 2018 – 2028 (US$M) |
Figure 9‑9: Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑10: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑11: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€) |
Figure 9‑12: Average Selling Price by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$) |
Figure 9‑13: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (€M) |
Figure 9‑14: Market Value by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 (US$M) |
Figure 9‑15: Units Sold by Country, Soft Tissue Platelet-Rich Plasma, Europe, 2018 – 2028 |
Figure 9‑16: Units Sold by Country, Spine Platelet-Rich Plasma, Europe, 2018 – 2028 |
Figure 9‑17: Units Sold by Country, Cardiac Platelet-Rich Plasma, Europe, 2018 – 2028 |
Figure 9‑18: Units Sold by Country, Orthopedic Platelet-Rich Plasma, Europe, 2018 – 2028 |
Figure 9‑19: Units Sold by Country, Plastics Platelet-Rich Plasma, Europe, 2018 – 2028 |
Figure 9‑20: Units Sold (10cc) by Country, Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑21: Units Sold (10cc) by Country, Soft Tissue Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑22: Units Sold (10cc) by Country, Trauma Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑23: Units Sold (10cc) by Country, Joint Reconstruction Bone Marrow Aspirate Concentrate Market, Europe, 2018 – 2028 |
Figure 9‑24: Leading Competitors by Country, Orthopedic Cell Therapy Market, Europe, 2021 |
Figure 10‑1: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 10‑2: Hyaluronic Acid Viscosupplementation Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 10‑3: Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 |
Figure 10‑4: Units Sold (Cycles) by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 |
Figure 10‑5: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€) |
Figure 10‑6: Average Selling Price by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$) |
Figure 10‑7: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (€M) |
Figure 10‑8: Market Value by Country, Total Hyaluronic Acid Viscosupplementation Market, Europe, 2018 – 2028 (US$M) |
Figure 10‑9: Single-Injection Market, Europe, 2018 – 2028 |
Figure 10‑10: Units Sold (Cycles) by Country, Single-Injection Market, Europe, 2018 – 2028 |
Figure 10‑11: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (€) |
Figure 10‑12: Average Selling Price by Country, Single-Injection Market, Europe, 2018 – 2028 (US$) |
Figure 10‑13: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (€M) |
Figure 10‑14: Market Value by Country, Single-Injection Market, Europe, 2018 – 2028 (US$M) |
Figure 10‑15: Two-Injection Market, Europe, 2018 – 2028 |
Figure 10‑16: Units Sold (Cycles) by Country, Two-Injection Market, Europe, 2018 – 2028 |
Figure 10‑17: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (€) |
Figure 10‑18: Average Selling Price by Country, Two-Injection Market, Europe, 2018 – 2028 (US$) |
Figure 10‑19: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (€M) |
Figure 10‑20: Market Value by Country, Two-Injection Market, Europe, 2018 – 2028 (US$M) |
Figure 10‑21: Three-Injection Market, Europe, 2018 – 2028 |
Figure 10‑22: Units Sold (Cycles) by Country, Three-Injection Market, Europe, 2018 – 2028 |
Figure 10‑23: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (€) |
Figure 10‑24: Average Selling Price by Country, Three-Injection Market, Europe, 2018 – 2028 (US$) |
Figure 10‑25: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (€M) |
Figure 10‑26: Market Value by Country, Three-Injection Market, Europe, 2018 – 2028 (US$M) |
Figure 10‑27: Five-Injection Market, Europe, 2018 – 2028 |
Figure 10‑28: Units Sold (Cycles) by Country, Five-Injection Market, Europe, 2018 – 2028 |
Figure 10‑29: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (€) |
Figure 10‑30: Average Selling Price by Country, Five-Injection Market, Europe, 2018 – 2028 (US$) |
Figure 10‑31: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (€M) |
Figure 10‑32: Market Value by Country, Five-Injection Market, Europe, 2018 – 2028 (US$M) |
Figure 10‑33: Leading Competitors by Country, Hyaluronic Acid Viscosupplementation Market, Europe, 2021 |
Figure 11‑1: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (€M) |
Figure 11‑2: Orthopedic Cartilage Repair Market by Segment, Europe, 2018 – 2028 (US$M) |
Figure 11‑3: Osteochondral Allograft Market, Europe, 2018 – 2028 |
Figure 11‑4: Meniscal Allograft Market, Europe, 2018 – 2028 |
Figure 11‑5: Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 |
Figure 11‑6: Units Sold by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 |
Figure 11‑7: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€) |
Figure 11‑8: Average Selling Price by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$) |
Figure 11‑9: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (€M) |
Figure 11‑10: Market Value by Country, Autologous Chondrocyte Implantation Market, Europe, 2018 – 2028 (US$M) |
Figure 11‑11: Osteochondral Autograft Market, Europe, 2018 – 2028 |
Figure 11‑12: Leading Competitors, Orthopedic Cartilage Repair Market, Europe, 2021 |
iData’s 9-Step Research Methodology
Our reports follow an in-depth 9-step methodology which focuses on the following research systems:- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.
Explore Options
Report Summary | FREE |
Orthopedic Biomaterials Market Size, Share and COVID-19 Impact Analysis | Europe | 2022-2028 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, and 3 more
$295 – $10,995
The European Orthopedic Biomaterials market report covers and includes the Bone Graft Substitutes Market, Orthopedic Growth Factor Market , Orthopedic Cell Therapy Market, Hyaluronic Acid Viscosupplementation Market, and the Orthopedic Cartilage Repair Market.
- 2022
- 10 Years
- Europe
- MedSuite
- 421
- 05/20/2022



